A Comprehensive Review of Retinal Gene Therapy

Shannon E Boye; Sanford L Boye; Alfred S Lewin; William W Hauswirth

doi:10.1038/mt.2012.280

journal article Open Access Mar 01, 2013

A Comprehensive Review of Retinal Gene Therapy

Shannon E Boye

Sanford L Boye

Alfred S Lewin William W Hauswirth

Molecular Therapy Vol. 21 No. 3 pp. 509-519 · Elsevier BV

View at Publisher Save 10.1038/mt.2012.280

Topics

No keywords indexed for this article. Browse by subject →

References

208

[1]

Rodieck (1998)

[2]

Jin "Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium" Cell (2005) 10.1016/j.cell.2005.06.042

[3]

Moiseyev "RPE65 is the isomerohydrolase in the retinoid visual cycle" Proc Natl Acad Sci USA (2005) 10.1073/pnas.0503460102

[4]

Redmond "Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle" Proc Natl Acad Sci USA (2005) 10.1073/pnas.0504167102

[5]

Cideciyan "Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy" Prog Retin Eye Res (2010) 10.1016/j.preteyeres.2010.04.002

[6]

Acland "Gene therapy restores vision in a canine model of childhood blindness" Nat Genet (2001) 10.1038/ng0501-92

[7]

Narfström "Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog" Invest Ophthalmol Vis Sci (2003) 10.1167/iovs.02-0595

[8]

Acland "Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness" Mol Ther (2005) 10.1016/j.ymthe.2005.08.008

[9]

Narfström "Assessment of structure and function over a 3-year period after gene transfer in RPE65-/- dogs" Doc Ophthalmol (2005) 10.1007/s10633-005-3159-0

[10]

Jacobson "Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection" Mol Ther (2006) 10.1016/j.ymthe.2006.03.005

[11]

Le Meur "Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium" Gene Ther (2007) 10.1038/sj.gt.3302861

[12]

Bennicelli "Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer" Mol Ther (2008) 10.1038/sj.mt.6300389

[13]

Narfström "Morphological aspects related to long-term functional improvement of the retina in the 4 years following rAAV-mediated gene transfer in the RPE65 null mutation dog" Adv Exp Med Biol (2008) 10.1007/978-0-387-74904-4_15

[14]

Aguirre "Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation" PLoS Med (2007) 10.1371/journal.pmed.0040230

[15]

Redmond "Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle" Nat Genet (1998) 10.1038/3813

[16]

Dejneka "In utero gene therapy rescues vision in a murine model of congenital blindness" Mol Ther (2004) 10.1016/j.ymthe.2003.11.013

[17]

Jacobson "Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success" Proc Natl Acad Sci USA (2005) 10.1073/pnas.0500646102

[18]

Chen "RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65-/- mice" Invest Ophthalmol Vis Sci (2006) 10.1167/iovs.05-0965

[19]

Pang "Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA)" Mol Vis (2005)

[20]

Pang "Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis" Mol Ther (2006) 10.1016/j.ymthe.2005.09.001

[21]

Roman "Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis" Mol Vis (2007)

[22]

Cideciyan "Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics" Proc Natl Acad Sci USA (2008) 10.1073/pnas.0807027105

[23]

Banin "Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel" Hum Gene Ther (2010) 10.1089/hum.2010.047

[24]

Wang "Intra-retinal visual cycle required for rapid and complete cone dark adaptation" Nat Neurosci (2009) 10.1038/nn.2258

[25]

Wang "An alternative pathway mediates the mouse and human cone visual cycle" Curr Biol (2009) 10.1016/j.cub.2009.07.054

[26]

Jacobson "Human cone photoreceptor dependence on RPE65 isomerase" Proc Natl Acad Sci USA (2007) 10.1073/pnas.0706367104

[27]

Bemelmans "Lentiviral vectors containing a retinal pigment epithelium specific promoter for leber congenital amaurosis gene therapy. Lentiviral gene therapy for LCA" Adv Exp Med Biol (2006) 10.1007/0-387-32442-9_35

[28]

Bemelmans "Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis" PLoS Med (2006) 10.1371/journal.pmed.0030347

[29]

Pang "Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency" Gene Ther (2010) 10.1038/gt.2010.29

[30]

Narfström "In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement" J Hered (2003) 10.1093/jhered/esg015

[31]

Li "Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis" Invest Ophthalmol Vis Sci (2011) 10.1167/iovs.10-6138

[32]

Maguire "Safety and efficacy of gene transfer for Leber's congenital amaurosis" N Engl J Med (2008) 10.1056/nejmoa0802315

[33]

Bainbridge "Effect of gene therapy on visual function in Leber's congenital amaurosis" N Engl J Med (2008) 10.1056/nejmoa0802268

[34]

Hauswirth "Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial" Hum Gene Ther (2008) 10.1089/hum.2008.107

[35]

Cideciyan "Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year" Hum Gene Ther (2009) 10.1089/hum.2009.086

[36]

Cideciyan "Vision 1 year after gene therapy for Leber's congenital amaurosis" N Engl J Med (2009) 10.1056/nejmc0903652

[37]

Maguire "Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial" Lancet (2009) 10.1016/s0140-6736(09)61836-5

[38]

Simonelli "Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration" Mol Ther (2010) 10.1038/mt.2009.277

[39]

Jacobson "Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years" Arch Ophthalmol (2012) 10.1001/archophthalmol.2011.298

[40]

Van Hooser "Rapid restoration of visual pigment and function with oral retinoid in a mouse model of childhood blindness" Proc Natl Acad Sci USA (2000) 10.1073/pnas.150236297

[41]

Van Hooser "Recovery of visual functions in a mouse model of Leber congenital amaurosis" J Biol Chem (2002) 10.1074/jbc.m112384200

[42]

Roman "Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials" Physiol Meas (2007) 10.1088/0967-3334/28/8/n02

[43]

Roman "Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures" Exp Eye Res (2005) 10.1016/j.exer.2004.09.008

[44]

Ferris "New visual acuity charts for clinical research" Am J Ophthalmol (1982) 10.1016/0002-9394(82)90197-0

[45]

Fishman "Outcome measures and their application in clinical trials for retinal degenerative diseases: outline, review, and perspective" Retina (Philadelphia, Pa) (2005) 10.1097/00006982-200509000-00014

[46]

Crossland "Preferred retinal locus development in patients with macular disease" Ophthalmology (2005) 10.1016/j.ophtha.2005.03.027

[47]

Butz "Activity-dependent structural plasticity" Brain Res Rev (2009) 10.1016/j.brainresrev.2008.12.023

[48]

Déruaz "Reading with multiple preferred retinal loci: implications for training a more efficient reading strategy" Vision Res (2002) 10.1016/s0042-6989(02)00354-1

[49]

Bennett "AAV2 gene therapy readministration in three adults with congenital blindness" Sci Transl Med (2012) 10.1126/scitranslmed.3002865

[50]

Mackay "Novel mutations in MERTK associated with childhood onset rod-cone dystrophy" Mol Vis (2010)

Showing 50 of 208 references

Cited By

218

Optical coherence tomography in children with inherited retinal disease

Jasleen K Jolly, Brent M Rodda · 2024

Clinical and Experimental Optometry

Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery

Yulia Eygeris, Michael I. Henderson · 2024

Small

Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR

Jasmina Cehajic-Kapetanovic, Kanmin Xue · 2020

Nature Medicine

Mouse γ-Synuclein Promoter-Mediated Gene Expression and Editing in Mammalian Retinal Ganglion Cells

Qizhao Wang, Pei Zhuang · 2020

The Journal of Neuroscience

The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective

Parviz Mammadzada, Pablo M. Corredoira · 2019

Experientia

Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye

Gerard A. Rodrigues, Evgenyi Shalaev · 2018

Pharmaceutical Research

Non-viral strategies for ocular gene delivery

Ana V. Oliveira, Ana M. Rosa da Costa · 2017

Materials Science and Engineering:...

Principles of pharmacology in the eye

Sahar Awwad, Abeer H A Mohamed Ahmed · 2017

British Journal of Pharmacology

Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60

Mohamed Mashal, Noha Attia · 2017

Journal of Controlled Release

Müller glial cell reprogramming and retina regeneration

Daniel Goldman · 2014

Nature Reviews Neuroscience

Metrics

218

Citations

208

References

Details

Published: Mar 01, 2013
Vol/Issue: 21(3)
Pages: 509-519
License: View

Authors

S

Shannon E Boye

Department of Pediatrics, Division of Cellular and Molecular Therapy, Gainesville, United States

S

Sanford L Boye

Department of Pediatrics, Powell Gene Therapy Center, Gainesville, United States

Cite This Article

Shannon E Boye, Sanford L Boye, Alfred S Lewin, et al. (2013). A Comprehensive Review of Retinal Gene Therapy. Molecular Therapy, 21(3), 509-519. https://doi.org/10.1038/mt.2012.280

A Comprehensive Review of Retinal Gene Therapy

You May Also Like